The invention relates to carbamates having general structure (I), wherein: R1,
R2 and R3 are H, OH, SH, CN, F, Cl, Br, I, (C1-C4)-alkylthio,
(C1-C4)-alkoxyl, (C1-C4)-alkoxyl substituted
by one or several F radicals, carbamoylamine, (C1-C4)-alkyl
and (C1-C4)-alkyl substituted by one or several F or OH radicals;
R4 represents a substituted or non-substituted cycloalkyl or cycloaryl radical
(a heteroalkyl radical or not). The amine of the quinuclidine ring can also be
forming quatemary ammonium salts or in an oxidized state (N-oxide). Carbamates
(I) are antagonists of the M3 muscarinic receptor, and selectively,
the M2 receptor. Hence, they can be used in the treatment of urinary
incontinence (particularly due to bladder instability), irritable bowel syndrome,
diseases of the respiratory tract (particularly chronic obstructive pulmonary disease,
chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmologic operations.
